Information for:

Clinical Pharmacy

Head of Cinical Pharmacy Department
Assoc. Prof. Mohamed Hassan Solayman

Email: mohamed.Solayman@guc.edu.eg
Office:
Ext:

Biography

Mohamed Solayman is currently a seconded Lecturer and Head of Clinical Pharmacy Unit, Faculty of Pharmacy and Biotechnology, GUC. He graduated from the Faculty of Pharmacy, Ain Shams University in 2006 and joined the Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University as a teaching assistant in 2007. Four years later, he defended his Master's thesis and was promoted to "Assistant Lecturer" position. In 2013, he was awarded a government-funded scholarship to conduct joint research for his PhD in the field of "pharmacogenetics" between Ain Shams University and University of Florida, Gainesville, FL, USA. In 2016, Mohamed defended his PhD thesis and then received faculty position as a Lecturer to start teaching undergraduate, Clinical Pharmacy Diploma, PharmD, and Master's courses side by side with conducting and supervising relevant research projects. Dr Solayman has actively participated in national and international conferences with posters and oral presentations and was nominated for a couple of awards in such meetings. His research experience is centered on pharmacogenetics, drug repurposing, and clinical research design and biostatistical analysis as tools to enhance the clinical pharmacy practice; hence, he has publications in peer-reviewed journals in such fields. Moreover, Dr Solayman is a consultant for a couple of regulatory authority scientific committees and board member in a number of educational programs

Research Interests

His research experience is centered on pharmacogenetics, drug repurposing, and clinical research design and biostatistical analysis as tools to enhance the clinical pharmacy practice; hence, he has publications in peer-reviewed journals in such fields. Moreover, Dr Solayman is a consultant for a couple of regulatory authority scientific committees and board member in a number of educational programs

Publications

2024

Journal 2024	Abdelgaied, M.Y., Rashad, M.H., El-Tayebi, H.M. et al. The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial. J Neurol 271, 1124–1132 (2024). https://doi.org/10.1007/s00415-023-12113-2
Journal 2024	El Gindy, D.M.K., Solayman, M.H., Khorshid, R. et al. Effect of Clinical and Genetic Factors on the Development of Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG) in Egyptian Patients Receiving Beta-Blockers. Cardiovasc Drugs Ther 38, 99–108 (2024). https://doi.org/10.1007/s10557-022-07380-6

2020

Journal 2020

Solayman MHM, Nassar NES, Abdel-kader SA, Afify S, Soltan H, Abdelghany AES, El-Wakeel LM, Hassany M. 2020. “PREVALENCE OF DRUG RESISTANCE IN NUCLEOSIDE/ NUCLEOTIDE ANALOGUE-TREATED EGYPTIAN PATIENTS WITH CHRONIC HEPATITIS B VIRUS”. Value in Health, 23, S168-169. IF 5.037

2019

Journal 2019	Sarhan NM, Shahin MH, El Rouby NM, El-Wakeel LM, Solayman MH, Langaee T, Khorshid H, Schaalan MF, Sabri NA, Cavallari LH. Effect of Genetic and Non-genetic Factors on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Egyptians with Heart Failure. Clin Transl Sci. 2019; doi: 10.1111/cts.12702.
Journal 2019	Mohamed H Solayman, Taimour Y Langaee, Yan Gong, Mohamed H Shahin, Stephen T Turner, Arlene B Chapman, John G Gums, Eric Boerwinkle, Amber L Beitelshees, Manal El-Hamamsy, Lamia El-Wakeel, Rhonda M Cooper-DeHoff, Osama A Badary, Julie A Johnson. Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies. European Journal of Pharmaceutical Sciences. 2019; 131: 93-98.
Poster 2019	Mohamed Solayman, Sarah Farid, Aya Ashraf, Yomna Ashraf, Toqa Hussein, Doha Ashraf, Nuhaa Mohammed, Salma Essam, Sarah Mohammed."Evaluation of Health-Related Quality of Life in HCV Egyptian Patients treated with the New Direct Acting Agents” "2019 Graduation project" Competition, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
Poster 2019	N Sarhan, NM El Rouby, MH Solayman, MH Shahin, T Langaee, H Khorshid, L El-Wakeel, MF Schaalan, NA Sabri, and LH Cavallari. "Effect of Genetic Polymorphism on the Clinical Response to Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure".. Clinical Pharmacology & Therapeutics, 2019.
Poster 2019	Mohamed H. Solayman, Edrees M. Helmy, Mohamed El-Hawary, Nour El-Houda Nazzal, and Youans Adel. "A Cross Sectional Study for Assessing the Knowledge, Attitude, and Practice of Pharmacovigilance in Egypt*". "2018 Graduation project" Competition, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt (Second Best Position) and ACCP virtual symposium, May, 2019

2018

Journal 2018	McDonough CW, Magvanjav O, Sa ACC, El Rouby NM, Dave C, Deitchman AN, Kawaguchi-Suzuki M, Mei W, Shen Y, Singh RSP, Solayman M, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Webb A, Scherer SE, Sadee W, Turner ST, Cooper-DeHoff RM, Gong Y, Johnson JA.. Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. Circ Genom Precis Med. 2018; 11(4):e001854.
Poster 2018	Solayman MH, Othman K, Ibrahim D, EL-sedik F, Gebily W. "Bacteriological Profile and Antibiogram of Neonatal Sepsis in the Neonatal Intensive Care Unit of an Egyptian Hospital". 2018 ISPOR Europe Meeting, Barcelona, Spain.
Poster 2018	Ahmed Salem, Ibrahim Abdelgawad, Mahmoud Tammam, and Mohamed Solayman. "Pharmacogenetics of Warfarin Dose Rquirements in the African Continent: A systematic Review". ACCP virtual symposium, May, 2018

2017

Journal 2017

Langaee TY, Stauffer L, Galloway C, Solayman MH, and Cavallari L. Cross-validation of High-Resolution Melting Analysis-Based genotyping platform. Genetic Testing and Molecular Biomarkers. 2017; 21(4):259-264..

Poster 2017

Mohamed H. Solayman, Taimour Langaee, Yan Gong, Stephen T. Turner, Arlene B. Chapman, John G. Gums, Eric Boerwinkle, Amber L. Beitelshees, Lamia El-Wakeel, Manal El-Hamamsy, Rhonda M. Cooper-DeHoff, Osama Badary, Julie A. Johnson."Association of Beta-1-Adrenergic Receptor (ADRB1) Gene Body DNA Methylation with Antihypertensive Response to Metoprolol in The Pharmacogenomic Evaluation of Antihypertensive Responses 2 (PEAR-2) Study" Clinical Pharmacology & Therapeutics 2017; 101: S47. (PI-106) (Top poster award).

2016

Journal 2016	Jahn SC, Solayman MH, Lorenzo RJ, Langaee T, Stacpoole PW, James MO. GSTZ1 expression and chloride concentrations modulate sensitivity of cancer cells to dichloroacetate. Biochim Biophys Acta. 2016; 1860(6):1202-10.
Journal 2016	Solayman MH, Langaee T, Patel A, El-Wakeel L, El-Hamamsy M, Badary O, Johnson JA. Identification of Suitable Endogenous Normalizers for qRT-PCR Analysis of Plasma microRNA Expression in Essential Hypertension. Mol Biotechnol. 2016; 58(3):179-87.
Journal 2016	Khalil BM, Shahin MH, Solayman MH, Langaee T, Schaalan MF, Gong Y, Hammad LN, Al-Mesallamy HO, Hamdy NM, El-Hammady WA, Johnson JA. Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population. Clin Transl Sci. 2016; 9(1):23-8.
Poster 2016	Stephan Jahn, Mohamed H. Solayman, Ryan Lorenzo, Taimour Langaee, Peter Stacpoole, Margret James. “Chemoresistance Through the Intratumoral Metabolism of Dichloroacetate” (Award-winning poster in the 28th Annual Research Showcase and Awards Recognition day, February 2015, University of Florida, FL, USA) Molecular Cancer Research 14(1 Supplement):A62-A62 · January 2016.

2015

Journal 2015	Langaee TY, Zhong G, Li W, Hamadeh I, Solayman MH, McDonough CW, Stacpoole PW, James MO. The influence of human GSTZ1 gene haplotype variations on GSTZ1 expression. Pharmacogenet Genomics. 2015; 25(5):239-45.
Poster 2015	Mohamed H. Solayman, Taimour Langaee, Yan Gong, Manal El-Hamamsy, Lamia El-Wakeel, Eric Boerwinkle, Arlene Chapman, Stephen Turner, John Gums, Amber Beitelshees, Rhonda Cooper-DeHoff, Osama Badary, Julie Johnson. “Association of Plasma MicroRNA with Antihypertensive Response to Beta Blockers". Clinical Pharmacology in Drug Development. 2015; 4(S1) 58-59. DOI:10.1002/cpdd.216, PMID: 27137874.
Poster 2015	Mohamed H. Solayman, Taimour Langaee, Archi Patel, Lamia El-Wakeel, Manal El-Hamamsy, Osama Badary, Julie Johnson. “Identification of Endogenous Control for Plasma miRNA Expression in Essential Hypertension” 28th Annual Research Showcase and Awards Recognition day, February 2015, University of Florida, FL, USA.

Dr. Dalia Sherif Elhelw

Email: dalia.khalil@guc.edu.eg
Office:B1-115

Email: danira.naeim@guc.edu.eg
Office:B1-207

Biography

Danira is a Postdoc Assistant Lecturer of Clinical Pharmacy and Pharmacotherapeutics in the faculty of Pharmacy and Biotechnology, German University in Cairo (GUC), Egypt.
She received her bachelor degree with highest honors from the faculty of Pharmacy and Biotechnology, GUC, in 2011. In the same year, she has been appointed as a teaching assistant at the GUC.
Habashy worked as a senior scientist in the “Molecular Pathology Research Group- MPRG” at the GUC, which was headed by Assoc. Prof Dr. Ahmed Ihab Abdelaziz and obtained her M.Sc. and PhD degrees in the field of Molecular Pharmacology in the period from 2011-2016. She received her PhD degree with excellence from the GUC in 2016, afterwards she has been appointed as an assistant lecturer in the GUC. During her post-doctoral period, she has supervised 3 Master projects and has publications and attended conferences in the field of oncology. She has been teaching various theoretical and practical courses in the Pharmacology and Toxicology department. In addition to teaching and research, she is also a member of the advising and internship committees.

Research Interests

Danira research interest focuses on epigenetic immuno-oncology and molecular regulation of certain immuno-modulatory proteins in liver, colorectal, pancreatic and breast cancers. In addition, the research team focuses on testing the effectiveness and toxicity of new chemotherapeutic agents on different cancer cell lines. The research group is composed of 2 PhD students and 9 M.Sc. students.

Publications

2022

Journal 2022	Photoactivatable properties of water-soluble fac-Mn(CO)3 bearing N^O bidentate ligand. Rabaa M. Khaled,a Danira A. Habashy,b Amr Y. Ahmed,b Omneya S. Ismael,c Sara S. Ibrahim,c Mennattallah Abdelfatah,c Krzysztof Radacki,d Ahmed M. Mansour,a.Polyhedron, (2022*).doi: https://doi.org/10.1016/j.poly.2022.116048. [project won the 2nd place in the biotechnology projects’ competitions in Cairo University, 28th of June 2022)
Journal 2022	Cytotoxicity of fac-Mn(CO)3 complexes with a bidentate quinoline ligand towards triple negative breast cancer. Danira A. Habashy, a Rabaa M. Khaled, b Amr Y. Ahmed, a Krzysztof Radacki, c Salma K. Ahmed, d Engy K. Tharwat, d Hana Magdy, d Alaa Zeinhom d and Ahmed M. Mansour b. Dalton Transactions. September 2022*. https://doi.org/10.1039/d2dt01938h
Journal 2022	Regulation of IGF2BP1 by miR-186 and its impact on downstream lncRNAs H19, FOXD2-AS1, and SNHG3 in HCC. Danira A. Habashy, Merna H Hamad, Manon Ragheb, Ziad A. Khalil, Shereen A. El Sobky, Karim A. Hosny, Gamal Esmat, Nada M. El-Ekiaby, Injie O. Fawzy, Ahmed I. Abdelaziz. Life Sciences, October (2022), https://doi.org/10.1016/j.lfs.2022.121075

2021

Conference 2021	MALAT-1: A Novel LncRNA Modulating STAT-3 Regulated Cystathionine-γ-lyase (CSE) in Breast Cancer. N. Khater, D. Habashy, R. Youness, M.Z. Gad; Annals of Oncology, 2021. Presented as an e-poster at the Virtual ESMO Congress (TAT), March 2021(received Merit Award).
Conference 2021	MALAT-1 and miR-486-5p: A novel lncRNA-miRNA circuit tuning IGF-1R and its downstream JAK/STAT pathway in Breast Cancer. Nour Khater, Rana Youness, Danira Habashy, Tamer Manie, Mohamed Zakaria Gad. Non coding RNA World: From Mechanism to Therapy Virtual Conference. Presented as an e-Poster, July 2021.
Conference 2021	MiR-486-5p/MALAT-1/IGF-1R: a novel miRNA-lncRNA-mRNA axis drawn downstream hydrogen sulfide in breast cancer. Nour Khater, Rana Youness, Danira Habashy, Mohamed Zakaria Gad. EMBO EMBL Symposium: The Non-Coding Genome, October 2021
Conference 2021	A Novel Crosstalk between Pyridoxal 5'-Phosphate (PLP)-Dependent Enzymes; CBS & CSE Modulated by MALAT-1/STAT-3 Axis. N. Khater, R. Ahmed Youness, D. Habashy, M.Z. Gad. Annals of Oncology. Presented as an e-poster at the Virtual ESMO Congress (MAP), October 2021.
Conference 2021	Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN): an example of the impact of COVID-19 pandemic on Clinical Research. Sara Araby, Mohamed Solayman, Danira Ashraf Habashy, Loay Kassem. Submitted abstract at AAICC, August 2021. Accepted as oral presentation.

2020

Conference 2020

Impact of CDK4 knock out using CRISPR/Cas9 Gene Editing Technology on Breast Cancer Progression. Amr Yehia, Danira Ashraf Habashy, Ahmed Bahaa, Hend El Tayebi and Hassan Adwan. European Journal of Cancer (EJC). Presented as a poster at the EBCC-12, Virtual Conference October 2020.

2019

Conference 2019

Impact of knocking out CCL4 expression using CRISPR Cas-9 technology on colorectal tumor progression. Roba Hamed Barakat, Danira Ashraf Habashy, Ahmed Bahaa and Hassan Adwan. Annals of Oncology, 2019. Presented as a poster at the ESMO Congress, in Barcelona, Spain, September 2019.

2018

Conference 2018	Does the long noncoding RNA HULC act as a sponge or as a downstream target for miR-186 in hepatocellular carcinoma? Danira Ashraf Habashy, Karim Adel Hosny, Gamal Esmat and Ahmed Ihab Abdelaziz. Annals of Oncology, 2018. Presented as a poster at the MAP (ESMO), in Paris, France, September 2018.
Book 2018	Early Metastasis in Colorectal Cancer Poses an Option for new Diagnostic and Treatment Strategies. Hassan Adwan, Dina El Harouni, Danira Habashy, Nadine ElBanna, Rania Georges, Martin Berger. Cancer Metastasis, 2018
Book 2018	The Extra Cellular Matrix in Colorectal Cancer: An Option for Novel Diagnostic and Treatment Strategies. Hassan Adwan, Danira Habashy, Nadine ElBanna, Dina El Harouni, Rania Georges, Martin Berger. HORIZONS IN CANCER RESEARCH, 2018

2016

Journal 2016

Interplay between microRNA-17-5p, insulin-like growth factor-II through binding protein-3 in hepatocellular carcinoma Danira Ashraf Habashy, Hend Mohamed El Tayebi, Injie Omar Fawzy, Karim Adel Hosny, Gamal Esmat, Ahmed Ihab Abdelaziz. World J Hepatol 2016 August 18; 8(23): 976-984

2013

Conference 2013

IMicroRNA-17-5p promotes tumorgenesis through the repression of IGFBP-3 and enhancement of Insulin like growth factor signaling Habashy DA, El Tayebi HM, Hosny KA, Esmat G. and Abdelaziz AI. VIRCHOWS ARCHIV, 2013, Volume 463, Issue 2, Pages 322-322 (Abstract). Presented as a poster at the 25th European Congress of Pathology Conference (ECP) 2013, in Lisbon, Portugal, September 2013

Assoc. Prof. Hend El Tayebi (Health Economics)

Email: hend.saber@guc.edu.eg
Office:B5-112
Ext:

Biography

With 13 years experience in the academic and research fields, El Tayebi is an assistant professor of Molecular Toxicology and Pharmacoeconomics and she is leading the “Molecular Pharmacology Research Group-MPRG” in the faculty of Pharmacy and Biotechnology, German University in Cairo (GUC), Egypt.

El Tayebi received her B.Sc. degree with highly honored excellence from faculty of Pharmacy and Biotechnology, GUC, in 2008. In 2009, she has been appointed as assistant lecturer of molecular pathology and pathophysiology at the GUC. And in 2014, she started teaching Cell Biology and Genetic Engineering as an assistant professor.

She pursued her M.Sc. and PhD studies in the field of Molecular Pharmacology in the period from 2008-2012. She received her PhD degree with “Summa cum laude” from the GUC in collaboration with the institute of Pathology, Heidelberg, Germany in 2012.

Hend established the Molecular Pharmacology research group- MPRG at the GUC in 2015. The MPRG focuses on pharmacogenomics of tumors and autoimmune diseases via epigenetic and molecular immuno-regulation of certain immuno-modulatory proteins in different cancers as well as autoimmune diseases such as Multiple Sclerosis. El Tayebi has supervised 20+ MSc. And PhD projects as well as B.Sc biotechnology project. The research group is composed of 2 PhD student, 20 M.Sc. students, 2 B.Sc. students and 10 undergraduate interns. MPRG is collaborating with several research groups worldwide in Germany, Netherlands and USA.

Through out her academic career, Hend has been invited as a guest speaker in more than 10 international conferences in Europe and MENA region, published and presented her research work in 30+ international conferences in Europe and USA (EASL, AASLD, Falling Wall of Berlin, ESMO, EMBO and more) and she has published 20+ paper publications in a high impact peer-reviewed international journals.

In 2015, She has pursued her MBA studies at the German university in Cairo with a double major of “International Business” and “Strategic Management”. Additionally, she studied Health Economics and research outcome in Utrecht university, the Netherlands in addition to the Arab Academy for Science and Transportation-AAST, Egypt where she received a diploma in health economics studies from. El Tayebi has been awarded the AAST award for achieving the 1st Rank on all AAST diploma programs in February 2020.

Research Interests

The Molecular Pharmacology Research Group focuses on genetic and epigenetic immunooncology and molecular regulation of certain immuno-modulatory proteins in liver and breast cancer as well as autoimmune diseases such as Multiple Sclerosis (MS). The team collaborates with several departments in the faculty of pharmacy and biotechnology at the GUC such as pharmaceutical biology (investigating the role of novel nutraceuticals on diseases epigenome), pharmaceutical chemistry (pharmacologic screening, testing and evaluation of novel compounds) and pharmaceutical technology (establishment of novel delivery systems and targeted therapies). El Tayebi has received several funds from DAAD and STDF.

Publications

2023

Journal 2023	MicroRNA 155 modulation of CD8+ T cell activity personalizes response to disease modifying therapies of patients with relapsing remitting multiple sclerosis. Elkhodiry AA, Zamzam DA, El Tayebi HM.Med Int (Lond). 2023 Mar 20;3(2):20. doi: 10.3892/mi.2023.80. eCollection 2023 Mar-Apr.PMID: 37032715 Free PMC article.
Journal 2023	Rs205764 and rs547311 in linc00513 may influence treatment responses in multiple sclerosis patients: A pharmacogenomics Egyptian study. Amin NS, Abd El-Aziz MK, Hamed M, Moustafa RR, El Tayebi HM.Front Immunol. 2023 Feb 17;14:1087595. doi: 10.3389/fimmu.2023.1087595. eCollection 2023.PMID: 36883100
Journal 2023	More gain, less pain: How resistance training affects immune system functioning in multiple sclerosis patients: A review. Amin NS, El Tayebi HM.Mult Scler Relat Disord. 2023 Jan;69:104401. doi: 10.1016/j.msard.2022.104401. Epub 2022 Nov 12.PMID: 36403379 Review.
Grant 2023	“Comprehensive screening and in-vitro analysis of PD-L1 small molecule inhibitors on a myriad of solid tumors: Hepatocellular carcinoma, colon cancer, pancreatic cancer and triple negative breast cancer” funded by the DAAD-BMBF
Grant 2023	Screening of Resistance- and Relapse-related Single Nucleotide Polymorphism in Hepatocellular Carcinoma Patients. (Project ID: 46300) Funded by the STDF
Grant 2023	Multi-dimensional screening of potential PD-1/PD-L1 immune checkpoint inhibitors as anti- hepatocellular carcinoma agents.” funded by ASRT

2022

Journal 2022	NEAT1: Culprit lncRNA linking PIG-C, MSLN, and CD80 in triple-negative breast cancer. Hussein NH, Eissa RA, de Bruyn M, El Tayebi HM.Life Sci. 2022 Jun 15;299:120523. doi: 10.1016/j.lfs.2022.120523. Epub 2022 Apr 2.PMID: 35378140
Journal 2022	CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer. Ghallab AM, Eissa RA, El Tayebi HM.Front Pharmacol. 2022 Apr 20;13:862125. doi: 10.3389/fphar.2022.862125. eCollection 2022.PMID: 35517812
Journal 2022	A cutting-edge immunomodulatory interlinkage between HOTAIR and MALAT1 in tumor-associated macrophages in breast cancer: A personalized immunotherapeutic approach. Amer HT, Eissa RA, El Tayebi HM.Front Mol Biosci. 2022 Oct 28;9:1032517. doi: 10.3389/fmolb.2022.1032517. eCollection 2022.PMID: 36387279
Journal 2022	The Monocyte, a Maestro in the Tumor Microenvironment (TME) of Breast Cancer. Amer HT, Stein U, El Tayebi HM.Cancers (Basel). 2022 Nov 7;14(21):5460. doi: 10.3390/cancers14215460.PMID: 36358879
Journal 2022	Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges. Kamal MA, Mandour YM, Abd El-Aziz MK, Stein U, El Tayebi HM.Molecules. 2022 Aug 28;27(17):5537. doi: 10.3390/molecules27175537.PMID: 36080304

2021

Grant 2021	Principle investigator of Academy of Scientific Research and Technology (ASRT) fund for project entitled: “Multi-dimensional screening of potential PD-1/PD-L1 immune checkpoint inhibitors as anti- hepatocellular carcinoma agents.” Proposal accepted in May 2021
Grant 2021	Principle investigator of DAAD/BMBF grant in collaboration with Prof. Ulrike Stein (Charite and Max-Delbruck Centre, Berlin, Germany). Project entitled: “CXCR2 Small Molecule Inhibitors: a Novel Approach to Combat Chemo-resistance and Augment Immunotherapy in Triple Negative Breast Cancer” Proposal accepted in December 2021.
Journal 2021	From Whole Blood to Isolated Pro-Metastasis Immune Cells: An Ex Vivo Approach to Isolate and Manipulate Immune Cells Contributing to Tumor Metastasis. Samir A, El Khodiry AA, ElTayebi HM. Methods Mol Biol. 2021 ;2294:209-218. doi: 10.1007/978- 1- 0716-1350-4_15.PMID: 33742404
Journal 2021	Oleuropin controls miR-194/XIST/PD-L1 loop in triple negative breast cancer: New role of nutri-epigenetics in immune-oncology. Hamed MM, Handoussa H, Hussein NH, Eissa RA, Abdel-Aal LK, El Tayebi HM.Life Sci. 2021 Mar 30;277:119353. doi: 10.1016/j.lfs.2021.119353. Online ahead of print.PMID: 33798547
Journal 2021	miR-155 and functional proteins of CD8+ T cells as potential prognostic biomarkers for relapsing-remitting multiple sclerosis Aya A Elkhodiry, Dina A Zamzam, Hend M El Tayebi , Mult Scler Relat Disord. 2021 Aug;53:103078. doi: 10.1016/j.msard.2021.103078. Epub 2021 Jun 11.
Journal 2021	Long non-coding RNAs XIST and MALAT1 hijack the PD-L1 regulatory signaling pathway in breast cancer subtypes. Samir A, Tawab RA, El Tayebi HM.Oncol Lett. 2021 Aug;22(2):593. doi: 10.3892/ol.2021.12854. Epub 2021 Jun 7.PMID: 34149904
Journal 2021	Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Atwa SM, Odenthal M, HM El Tayebi.Cancers (Basel). 2021 Aug 27;13(17):4343. doi: 10.3390/cancers13174343.PMID: 34503153
Journal 2021	Scavenging the hidden impacts of non-coding RNAs in multiple sclerosis.Elkhodiry AA, El Tayebi HM.Noncoding RNA Res. 2021 Dec 7;6(4):187-199. doi: 10.1016/j.ncrna.2021.12.002. eCollection 2021 Dec.PMID: 34938929
Journal 2021	Thymoquinone: A Tie-Breaker in SARS-CoV2-Infected Cancer Patients? Elgohary S, Elkhodiry AA, Amin NS, Stein U, El Tayebi HM.Cells. 2021 Feb 2;10(2):302. doi: 10.3390/cells10020302.PMID: 33540625
Conference 2021	CXCR2 Small Molecule Antagonists: a Novel Approach to Enhance the Effect of PDL-1 Inhibitors in Triple Negative Breast Cancer, ESMO Breast Cancer Virtual Congress, May 2021. Alaa Ghallab , Reda A. Eissa and Hend M. El Tayebi
Conference 2021	CXCR2 Antagonist Revoked TGF- β Elevation in Chemo-resistant Triple Negative Breast Cancer Cells. ESMO ImmunOncology Conference, Geneva, December 2021 Alaa Ghallab, Reda Eissa, Hend M. El Tayebi
Conference 2021	Combined efforts of LncRNAs DILC and Atezolizumab to regulate MMP-9 release in tumor microenvironment of TNBC TAMs and cells lines. ESMO ImmunOncology Conference, Geneva, December 2021. Amany Samir, Reda Eissa, Ulrike Stein, Hend M. El Tayebi
Conference 2021	Paracrine Crosstalk between LncRNA DILC and TNF-α release in tumor microenvironment of triple negative breast cancer Amany Samir, Reda Eissa, Ulrike Stein, Hend M. El Tayebi. ESMO ImmunOncology Conference, Geneva, December 2021

2020

Journal 2020	LncRNAs; XIST and MALAT1 hijack PD-L1 regulatory pathway in breast cancer subtypes. Amany Samir, Reda A. Eissa and Hend M. El Tayebi, Oncology Letters, December 2020 (In production and Proofreading)
Journal 2020	GPI-AP: Unraveling a New Class of Malignancy Mediators and Potential Immunotherapy Targets Nada H. Hussein, Nada S. Amin and Hend M. El Tayebi* , Front. Oncol., 04 December 2020 \| https://doi.org/10.3389/fonc.2020.537311
Journal 2020	Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma. Sara M Atwa, Heba Handoussa, Karim M Hosny, Margarete Odenthal and Hend M El Tayebi, World Journal of Hepatology, October 2020 (ahead of print)
Journal 2020	MALAT-1: LncRNA ruling miR-182/PIG-C/mesothelin triad in triple negative breast cancer. Barsoum FS, Awad AS, Hussein NH, Eissa RA, El Tayebi HM.Pathol Res Pract. 2020 Nov 4;216(12):153274. doi: 10.1016/j.prp.2020.153274. Online ahead of print.PMID: 33171372
Journal 2020	XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients Esraa A Salama, Reda E Adbeltawab, Hend M El Tayebi, Front Oncol, 9, 1459 2020 Jan 10. PMID: 31998636, PMCID: PMC6966712 DOI: 10.3389/fonc.2019.01459
Journal 2020	Pivotal role of long non-coding ribonucleic acid-X-inactive specific transcript in regulating immune checkpoint programmed death ligand 1 through a shared pathway between miR-194-5p and miR-155-5p in hepatocellular carcinoma. Atwa SM, Handoussa H, Hosny KM, Odenthal M, Tayebi HME.World J Hepatol. 2020 Dec 27;12(12):1211-1227. doi: 10.4254/wjh.v12.i12.1211.PMID: 33442449
Conference 2020	Virtual Screening and biological evaluation of potential PD-1/PD-L1 immune checkpoint inhibitors as anti-hepatocellular carcinoma agents. American Association for the Study of Liver Diseases, AASLD Congress November 2020. Monica A. Kamal , Yasmine M. Mandour , Hedy A. Badry , Dalia Omran , Hend I. Shoushaa, Ashraf O. Abdelaziz, and Hend M. El Tayebi
Conference 2020	Tackling TGF-β mediated Doxorubicin Chemoresistance by AZD5069 in Triple Negative Breast Mammospheres. ESMO Congress, September 2020 (Virtual) Alaa Ghallab , Reda A. Eissa and Hend M. El Tayebi
Conference 2020	Abrogation of Taxol® Chemo-resistance via Epigenetic Immune Checkpoints Regulation in Triple Negative Breast Cancer. ESMO Breast Cancer May 2020, Berlin. S. El Shihy, M. Armanious, R. Abdeltawab and H. M. El Tayebi
Conference 2020	MALAT-1 ruling the miR-182/PIG-C/MSLN triad in triple negative breast cancer ESMO Breast Cancer May 2020, Berlin. A. Samir, F. Barsoum, R. Abdeltawab and H. M. El Tayebi
Book Chapter 2020	Book Chapter titled: From whole blood to isolated pro-metastasis immune cells: an exvivo approach to isolate and manipulate immune cells contributing to tumor metastasis. Book name: Nature Protocols. Accepted March 2020 (in Online Publication process)

2019

Journal 2019	Methylation in MIRLET7A3 Gene Induces the Expression of IGF-II and Its mRNA Binding Proteins IGF2BP-2 and 3 in Hepatocellular Carcinoma. Waly AA, El-Ekiaby N, Assal RA, Abdelrahman MM, Hosny KA, El Tayebi HM, Esmat G, Breuhahn K, Abdelaziz AI. Front Physiol. 2019 Jan 24;9:1918. doi: 10.3389/fphys.2018.01918. eCollection 2018. PMID: 30733684 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353855/
Conference 2019	NEAT-1: culprit LncRNA tying PIG-C, MSLN, CD80 in TNBC.ESMO congress 2019, Barcelona N.H. Hussein, H.M. El Tayebi, M. de Bruyn, Annals of Oncology (2019)30(suppl_5): v760-v796. 10.1093/annonc/mdz268.
Conference 2019	Pivotal role of XIST in regulating immune checkpoint PD-1/PD-L1 through a shared pathway between miR-194-5p and miR-155-5p in Hepatocellular carcinoma. EASL HCC Summit 2019, Lisbon. S. Atwa, K. Hosny,, H. Handoussa and H. M. El Tayebi

Conference 2019	NEAT-1: culprit LncRNA tying PIG-C, MSLN, CD80 in TNBC.ESMO congress 2019, Barcelona N.H. Hussein, H.M. El Tayebi, M. de Bruyn, Annals of Oncology (2019)30(suppl_5): v760-v796. 10.1093/annonc/mdz268.
Conference 2019	Pivotal role of XIST in regulating immune checkpoint PD-1/PD-L1 through a shared pathway between miR-194-5p and miR-155-5p in Hepatocellular carcinoma. EASL HCC Summit 2019, Lisbon. S. Atwa, K. Hosny,, H. Handoussa and H. M. El Tayebi

2018

Journal 2018	Behind the curtain of non-coding RNAs; long non-coding RNAs regulating hepatocarcinogenesis.El Khodiry A, Afify M, El Tayebi HM.World J Gastroenterol. 2018 Feb 7;24(5):549-572. doi: 10.3748/wjg.v24.i5.549. Review.PMID:29434445
Conference 2018	Paradoxically functioning onco-miR-155 and the tumor suppressor miR-194 consensus on PD-L1 immune checkpoint upregulation via MALAT1 and XIST in hepatocellular Carcinoma. April 2018, Journal of Hepatology, The International Liver Congress, EASL 2018.S. Atwa, K. Hosny,, H. Handoussa and H. M. El Tayebi
Book Chapter 2018	“Non-Coding RNAs as Future Cancer Biomarkers” Salama E.A. and El Tayebi H.M. Book name: Cancer Therapy Publisher: MedDocs International
Book Chapter 2018	"The Era of Immunotherapy in Breast Cancer” Samir, A. and El Tayebi H.M. Book name: Cancer Therapy Publisher: MedDocs International
Conference 2018	PIG-C and SOCS3; potential immunotargets regulated by non-coding RNAs in TNBC Dec 2018, ESMO Immuno-Oncology Congress. Monia Mohsen, Reda Abdeltawab and Hend M. El Tayebi

2017

Journal 2017	Destabilizing the interplay between miR-1275 and IGF2BPs by Tamarix articulata and quercetin in hepatocellular carcinoma. Shaalan YM, Handoussa H, Youness RA, Assal RA, El-Khatib AH, Linscheid MW, El Tayebi HM, Abdelaziz AI. Nat Prod Res. 2017 Aug 18:1-4. doi: 10.1080/14786419.2017.1366478. [Epub ahead of print]PMID:28817968
Journal 2017	MiR-615-5p depresses natural killer cells cytotoxicity through repressing IGF-1R in hepatocellular carcinoma patients.Rahmoon MA, Youness RA, Gomaa AI, Hamza MT, Waked I, El Tayebi HM, Abdelaziz AI. Growth Factors. 2017 Jun;35(2-3):76-87. doi: 10.1080/08977194.2017.1354859. Epub 2017 Jul27.PMID:28747084
Conference 2017	43PXIST and TSIX: Novel cancer-immune biomarkers showing differential expression in tumor, PBMCs, serum, nipple discharge and lymph nodes of PD-L1 overexpressing BC patients. Dec 2017, Annals of Oncology, E Atef R Abdel Tawab Hend M. El Tayebi
Conference 2017	42PDifferential expression of PD-L1, MALAT1 and XIST in tumors and lymph nodes of TNBC and IDC patients and their regulation by miR-182. Dec 2017, Annals of Oncology, A Samir R Abdel Tawab, Hend M. El Tayebi
Conference 2017	Regulation of PD-L1 immune check point by onco-miR-155 via LncRNA-MALAT-1 expression manipulation in hepatocellular carcinoma.Nov. 2017, EMBL. S. Atwa, K. Hosny,, H. Handoussa and H. M. El Tayebi
Conference 2017	Long non-coding RNAs, MALAT-1 and XIST: novel immune check point regulators manipulating PDL-1 expression under the control of mir-182 in breast cancer. Nov. 2017, EMBL, A. Samir R Abdel Tawab, Hend M. El Tayebi

2016

Journal 2016	miR-34a: Multiple Opposing Targets and One Destiny in Hepatocellular Carcinoma.Yacoub RA, Fawzy IO, Assal RA, Hosny KA, Zekri AN, Esmat G, El Tayebi HM, Abdelaziz AI. J Clin Transl Hepatol. 2016 Dec 28;4(4):300-305. doi: 10.14218/JCTH .2016.00031. Epub 2016 Dec 27.PMID:28097098
Journal 2016	MicroRNA-486-5p enhances hepatocellular carcinoma tumor suppression through repression of IGF-1R and its downstream mTOR, STAT3 and c-Myc. Youness RA, El-Tayebi HM, Assal RA, Hosny K, Esmat G, Abdelaziz AI. Oncol Lett. 2016 Oct;12(4):2567-2573. Epub 2016 Jul 27.PMID:27698829
Journal 2016	Interplay between microRNA-17-5p, insulin-like growth factor-II through binding protein-3 in hepatocellular carcinoma.Habashy DA, El Tayebi HM, Fawzy IO, Hosny KA, Esmat G, Abdelaziz AI. World J Hepatol. 2016 Aug 18;8(23):976-84. doi: 10.4254/wjh.v8.i23.976.PMID:27621763
Journal 2016	Contradicting interplay between insulin-like growth factor-1 and miR-486-5p in primary NK cells and hepatoma cell lines with a contemporary inhibitory impact on HCC tumor progression.Youness RA, Rahmoon MA, Assal RA, Gomaa AI, Hamza MT, Waked I, El Tayebi HM, Abdelaziz AI.Growth Factors. 2016 Aug;34(3-4):128-40. doi: 10.1080/08977194. 2016.1200571. Epub 2016 Jul 8.
Review 2016	Epigenetic regulation of insulin-like growth factor axis in hepatocellular carcinoma. El Tayebi H M, Abdelaziz A I, World Jorunal of Gastroenetrology, March 2016 (ahead of print)
Conference 2016	29PXIST overrides the regulatory effect of miR-194 on its immunomodulatory target PD-L1 in breast cancer. Nov 2016, Annals of Oncology, Marwa Hamed R.A.E. Eissa Lobna Kassem Hend M. El Tayebi
Conference 2016	Restoring The Expression of Endogenous IGF-1 by miR-486 in NK Cells of HCC Patients Augments Its Cytotolytic Activity Against Hepatoma Cell Lines Apr 2016, Journal of Hepatology– EASL International Liver Congress, Barcelona, Spain. Rana A. Youness, Mai A. Rahmoon, Asmaa Gomaa, Imam Waked, Hend M El Tayebi., Ahmed I. Abdelaziz
Conference 2016	miR-155: A Double Faced microRNA With Respect to its impact on Tumorigenesis in Both Natural Killer Cells and Their Target Hepatocytes Apr 2016, Journal of Hepatology– EASL International Liver Congress, At Barcelona, Spain. Mai A. Rahmoon,Rana A. Youness, Asmaa Gomaa, Imam Waked, Hend M. El Tayebi, Ahmed I. Abdelaziz,

2015

Journal 2015	miR-1275: A single microRNA that targets the three IGF2-mRNA-binding proteins hindering tumor growth in hepatocellular carcinoma.Fawzy IO, Hamza MT, Hosny KA, Esmat G, El Tayebi HM, Abdelaziz AI. FEBS Lett. 2015 Aug 4;589(17):2257-65.
Conference 2015	Modulating the Expression of the Activating Receptor NKG2D and the Inhibitory Receptor NKG2A of NK cells by miR-182 in HCC. Mohamed M. Abdelrahman*, Injy O. Fawzy, Asmaa I. Gomaa, Imam Waked, Gamal Esmat, Hend M. El Tayebi, Ahmed I. Abdelaziz..5th Clinical Epigenetics International Meeting March 5th - 6th, 2015, Düsseldorf, Germany
Conference 2015	IMPROVING NATURAL KILLER CELLS CYTOTOXICTY AND HARNESSING HEPATOCYTE CANCER PROGRESSION BY MIR-486-5P. Aya A. Bassiouni* , Mai A. Rahmoon1, Rana A. Youness, Asmaa I. Gomaa, Imam Waked, Gamal Esmat3, Hend M. El Tayebi, Ahmed I. Abdelaziz. European Associaton for the study of Liver, Vienna, EASL 2015 (Poster Presentation).
Book 2015	"miR-486-5p and Liver Cancer Therapy: A Beautiful Mind Act” Rana Ahmed youness. Hend M. El Tayebi • Asmaa I. Gomaa • Imam Waked • Gamal Esmat • Ahmed Ihab AbdelAziz Published by: Lambert Academic Publishing (LAP)
Book 2015	“miR-615 and miR-155: microRNAs governing HCC in a paradoxical manner” Hend M. El Tayebi , PhD and Ahmed I. Abdelaziz, MD,PhD.

2014

Journal 2014	Transcriptional activation of IGF-II/IGF-1R axis and inhibition of IGFBP-3 by miR-155 in hepatocellular carcinoma. El Tayebi H.M., Waly A.A., Assal R.A., Hosny K.A., Esmat G. and Abdelaziz A.I., Oncology Letters, (November 2014)
Journal 2014	A pleiotropic effect of the single clustered hepatic metastamiRs miR-96-5p & miR-182-5p on IGF-1R, IGFBP-3 and IGF-II in Hepatocellular carcinoma. R. A.Assal , H. M.El Tayebi , K. A. Hosny , G.Esmat , A. I. Abdelaziz, Molecular Medicine Reports (June 2014)
Journal 2014	miR-155 induces mTOR expression via activation of IGF-II/IGF-1R axis and inhibitionof IGFBP-3 in Hepatocellular Carcinoma.. Hend M. El Tayebi; Amr A. Waly; Rana A. Youness; Mai A. Rahmon; Aya A. Bassiouni; Reem A. Assal; Karim A. Hosny; Gamal Esmat; Ahmed I. Abdelaziz.. American Association for Cancer Research (AACR), Philadelphia, USA. September 2014 (Poster Presentation)
Conference 2014	A coach, a playmaker, a defender and strikers: an epigenetic-target interplay in HCV/HCC.M.M. Fouad, N.M. Elemam, H.B. Sherif, S.A. El Sobky, R.A. Yacoub, A.K. Abelhamid, T. Elbaz, M.A. Mohey El Din , I.O. Fawzy , H.M. El Tayebi ,N. El-Ekiaby, R.Y. Mekky, G. Esmat ,A.I. Abdelaziz.European Associaton for the study of Liver, London, EASL 2014 (Poster Presentation).
Conference 2014	Unshielding IGF-II mRNA by targeting IGF2BPs through demethylating the Let-7a-3 gene in HCC cell lines. Waly A.A. ,El Tayebi H.M., Hosny K.A., Esmat G. and Abdelaziz A.I.HCC Summit, EASL, Geneva 2014

2013

Journal 2013	A Missing Correlation between the Number and Type of MEFV Mutations and Severity of Clinical Manifestations in Egyptian Pediatric FMF Patients. Injie O. Fawzy, Hend M. El. Tayebi, Menna M. El. Wassal, Farah H. El. Bibany, Samia Salah, Ahmed I. Abdelaziz , British Journal of Medicine and Medical Research, 2013.
Journal 2013	Detection of Y chromosome microdeletions in recurrent abortions among Egyptian females using SYBR Green Real Time PCR. Said M.M, Fahmi A.A, Hemeda H.M, Aly B, AbdelAal R.H, Nasr S.M, El Gamal M, Fawzy I.O, El Tayebi H.M, Abdelaziz A.I , Journal of American Science , 2013.
Journal 2013	Repression of miR-17-5p with elevated expression of E2F-1 and c-MYC in non-metastatic Hepatocellular Carcinoma and enhancement of cell growth upon reversing this expression pattern. H M El Tayebi, K Omar, S Hegy, M El Maghrabi, M El Brolosy, K A Hosny, G Esmat, A I Abdelaziz , Biochemical and Biophysical Research Communications, 2013.
Conference 2013	Failure of induction of the oncomiRic cluster miR-182/miR-96 in HCV-induced non-metastatic hepatocellular carcinoma tissues renders them as markers for metastasis.Asal R.A., El Tayebi H.M., Hosny K.A., Esmat G. and Abdelaziz A.I. European Society of Pathology, Lisbon 2013 (Oral presentation)
Conference 2013	MicroRNA-17-5p promotes tumorgenesis through the repression of IGFBP-3 and enhancement of Insulin-like growth factor signaling. Habashy D.A., El Tayebi H.M., Hosny K.A., Esmat G. and Abdelaziz A.I.European Society of Pathology, Lisbon 2013 (Poster presentation)
Conference 2013	Hypermethylation of MicroRNA let-7a-3 Gene Represses the Primary and Mature let-7a-3 with an Inverse Corelation to IGF-II mRNA in HCV-induced Hepatocellular Carcinoma. Waly A., El Tayebi H.M., Hosny K.A., Esmat G. , and Abdelaziz A.I.. European Associaton for the study of Liver, Amesterdam, EASL 2013 (Poster Presentation
Book 2013	“miR-615-5p and miR-155-5p in Hepatocellular Carcinoma Immunotherapy” Mai Atef, Rana Ahmed youness, Hend M. El Tayebi, Asmaa I. Gomaa, Imam Waked, Gamal Esmat, Ahmed Ihab AbdelAziz Published by: Lambert Academic Publishing (LAP)

2012

Journal 2012	miR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma. H M El Tayebi, K A Hosny, G Esmat, K Breuhahn, Ahmed Ihab Abdelaziz , FEBS letters , 2012.
Conference 2012	E2f-1 Transcript Knock Down via oncomiR-17-5p gain of function in Hepatocellular Carcinoma Cell Lines. El Tayebi H.M., Omar K., Hosny K.A., Esmat G. and Abdelaziz A.I.Humboldt Kolleg “Pharmaceutical and Biotechnological Therapies” September 2012 (Poster presentation)
Conference 2012	MiR-155 is an inducer for the insulin-like growth factor II mitogenic signaling pathway in HCV-progressed hepatocellular carcinoma.H.M. El Tayebi, K.A. Hosny, G. Esmat, K. Breuhahn, A.I. Abdelaziz.,European Associaton for the study of Liver, Barcelona, EASL 2012 (Poster Presenation).

2011

Journal 2011

Expression of Insulin-like Growth Factor-II, Matrix Metalloproteinases and their tissue inhibitors as predictive markers in the peripheral blood of HCC patients. El Tayebi H, Salah W, El Sayed I, Zekri AR , Zayed N, Salem S, Esmat G and Abdelaziz AI : , Biomarkers, 2011.

2010

Conference 2010

Positive correlation between the up-regulated Matrix Metalloproteinases and their down-regulated tissue inhibitors with the clinical staging of Hepatocellular Carcinoma Patients. El Tayebi H.M, Salah W., Elsayed I.H., Zekri A., Esmat G. and Abdelaziz A.I. , ICMCO, 2010.

2009

Conference 2009

Dysregulation of the Overexpressed Insulin like growth Factor II (IGFII) by Tissue inhibitor of Metalloproteinases (TIMP1) in the peripheral blood of Patients with Hepatocellular Carcinoma. Eltayebi H, Zekri Abdelrahman and Abdelaziz AI : , 5th APASL Single topic conference, 2009.

Prof. Peter Ruth

Mayar Waleed Salaheldin (PhD. Candidate)

Email: mayar.waleed@guc.edu.eg
Office:B1.205
Ext:

Mai Mohamed Tarek Ghannoum (PhD. Candidate)

Email: mai.tarek@guc.edu.eg
Office:B1.205
Ext:

Deanship

Departments

Biochemistry

Clinical Pharmacy

Microbiology, Immunology and Biotechnology

Pharmaceutical Biology

Pharmaceutical Chemistry

Pharmacology and Toxicology

Pharmaceutical Technology

Academic Coordinators

Academic Committees

Ethics Committee

Teaching Assistants Support Committee

Academic Curriculum Committee

Academic Training Committee

Admission - Apply Now Online

GUC Berlin

Webmail

Student Portal

Accredited By:

Clinical Pharmacy

Head of Cinical Pharmacy Department Assoc. Prof. Mohamed Hassan Solayman

Biography

Research Interests

Publications

2024

2020

2019

2018

2017

2016

2015

Dr. Dalia Sherif Elhelw

Biography

Research Interests

Publications

2018

2017

2014

Dr. Danira Ashraf Habashy

Biography

Research Interests

Publications

2022

2021

2020

2019

2018

2016

2013

Assoc. Prof. Hend El Tayebi (Health Economics)

Biography

Research Interests

Publications

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

Prof. Peter Ruth

Mayar Waleed Salaheldin (PhD. Candidate)

Mai Mohamed Tarek Ghannoum (PhD. Candidate)

Biography

Head of Cinical Pharmacy Department
Assoc. Prof. Mohamed Hassan Solayman